Developer docs
API playgroundTry for free, no card

Search company profiles

City Therapeutics

Full company profile

uuid0000bnt

Namestring
City Therapeutics
Legal namestring
CITY THERAPEUTICS, INC.
Websiteurl
citytx.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

City Therapeutics, Inc. is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company founded in October 2024 by former Alnylam Pharmaceuticals RNAi pioneers, including John Maraganore, Ph.D. (founding CEO of Alnylam, now Executive Chair) and several co-founders with deep Alnylam lineage. The company is developing next-generation RNA interference (RNAi) therapeutics built on a proprietary engineering platform centered on cityRNA (Cleavage-Inducing Tiny RNAs) trigger molecules paired with novel targeting ligands that enable extra-hepatic delivery of siRNAs to tissues beyond the liver, including ocular, CNS, and other tissue types. This extra-hepatic capability is positioned as a key differentiator from current FDA-approved RNAi medicines, which are largely restricted to liver targets.

The company's lead clinical asset is CITY-FXI, a Factor XI-targeting RNAi therapeutic in Phase 1 development in the United Kingdom for thromboembolic diseases, designed to provide anticoagulation with reduced bleeding risk. Its second disclosed program is CITY-RBP4, a preclinical RNAi therapy targeting RBP4 for Stargardt disease and geographic atrophy, with a planned regulatory submission in mid-2026. The pipeline also includes undisclosed hepatic, ocular, and CNS programs, with the company targeting 1-2 INDs per year starting in 2026.

City Therapeutics is pre-revenue and has not yet commercialized any product. Its business model combines future drug commercialization with licensing and partnership economics: it has entered strategic collaborations with Biogen (up to approximately $1 billion in potential milestones plus tiered royalties for CNS) and Bausch + Lomb (up to $485 million in milestones plus royalties for geographic atrophy), each including convertible note investments representing minority equity. To date the company has raised over $230 million across a $135 million Series A (October 2024, led by ARCH Venture Partners) and a $99.5 million Series B (June 2026, led by Viking Global Investors and Sofinnova Investments), with stated runway through 2027.

Short descriptiontext

City Therapeutics is a Cambridge, MA-based clinical-stage biopharmaceutical company developing next-generation RNA interference (RNAi) therapeutics using proprietary cityRNA trigger molecules and extra-hepatic delivery technology to address diseases including thromboembolic disorders, Stargardt disease, and geographic atrophy, serving patients with significant unmet medical need.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNAi therapeutics, siRNA engineering, biopharmaceutical development, gene silencing medicines, extra-hepatic drug delivery
Industry5 codes
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
RNAi Therapeutics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Drug Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotech developing RNAi therapeutics for rare diseases and specialty conditions. Revenue will come from product sales upon regulatory approval.

genengnews.com
2Partnership Milestone Payments
TypeLicensing Royalties
Description

Upfront payments and development milestones from strategic partnerships including up to approximately $1 billion from Biogen and up to $485 million from Bausch + Lomb, plus tiered royalties on net sales

citytx.com
3Equity Investments from Partners
TypeLicensing Royalties
Description

Strategic investments from pharmaceutical partners including $30 million convertible note from Biogen and convertible note from Bausch + Lomb representing minority equity interest

citytx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

City Therapeutics develops next-generation RNA interference (RNAi)-based therapeutics using its proprietary cityRNA engineering platform. The company is advancing a pipeline of investigational medicines targeting Factor XI for thromboembolic diseases and RBP4 for Stargardt disease and geographic atrophy, leveraging novel siRNA trigger molecules and extra-hepatic delivery technologies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • CITY-RBP4 suppressed RBP4 and reduced circulating retinol by approximately 90% at 3 mg/kg dose in non-human primates with duration consistent with quarterly or biannual dosing
+2 more records
Product overview1 text field

City Therapeutics is developing a pipeline of next-generation RNAi-based medicines using its proprietary cityRNA technology platform. The company's core products include CITY-FXI (Phase 1 clinical trial for thromboembolic diseases targeting Factor XI) and CITY-RBP4 (preclinical/IND-enabling stage for Stargardt disease and geographic atrophy). The platform enables extra-hepatic delivery of RNAi therapeutics to reach tissues beyond the liver, expanding the therapeutic reach of RNA interference medicines across multiple disease areas including coagulation, ophthalmology, and CNS disorders.

Product and service3 records
1CITY-FXI
CategoryRNAi Therapeutic
Description

A next-generation RNAi therapeutic candidate targeting Factor XI (FXI) for the prevention of thromboembolic diseases, designed to provide safe anticoagulation with reduced bleeding risk compared to standard-of-care therapies and supporting a simple dosing schedule.

2CITY-RBP4
CategoryRNAi Therapeutic
Description

An investigational RNAi therapy targeting RBP4 for the treatment of Stargardt disease and geographic atrophy, which silences hepatic expression of the vitamin A carrier protein to reduce toxic retinoid accumulation in the retina.

3cityRNA Technology Platform
CategoryTechnology Platform
Description

A next-generation RNAi engineering platform that enables the design of novel trigger molecules (cityRNAs) with improved potency, specificity, and cellular uptake, paired with precision targeting ligands for extra-hepatic delivery beyond the liver.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-27
Description

Strategic collaboration to develop select novel RNAi therapies for CNS diseases. City Therapeutics leveraging next-generation RNAi engineering technologies combined with Biogen's proprietary drug delivery technology. City receives $16M upfront + $30M convertible note investment, eligible for up to ~$1B in milestones plus tiered royalties. Biogen handles IND-enabling studies and global clinical development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-10
Description

Strategic collaboration focused on development of novel RNAi therapy for geographic atrophy (advanced form of age-related macular degeneration). City leverages next-generation RNAi engineering for intravitreal administration. City eligible for up to $485M in milestones plus royalties. Bausch + Lomb responsible for IND-enabling through commercialization.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Arrowhead develops RNAi-based therapeutics using its TRiM platform with strong focus on extra-hepatic delivery (lung, muscle, CNS, oncology) — directly overlapping with City's cityRNA/extra-hepatic strategy. Comparable clinical-stage pipeline dynamics and partnering model (e.g., Sarepta, Takeda, Amgen deals).

TypeDirect peer
Description

Sirnaomics develops RNAi-based therapeutics using its PNP (Polypeptide Nano-Particle) delivery platform targeting hepatic and extra-hepatic tissues (e.g., oncology, fibrosis, ocular). Comparable modality, stage, and focus on delivery beyond the liver.

TypeEmerging player
Description

Wave develops stereopure oligonucleotide therapeutics (RNAi-like siRNA and other modalities) with a platform analogous to city's cityRNA engineering, focused on CNS, hepatic and extra-hepatic targets. Comparable in clinical stage, modality and pipeline scope.

TypeEmerging player
Description

Editas develops gene-editing and CRISPR-based therapies, with City CMO Baisong Mei previously serving as EVP/CMO. Comparable as a clinical-stage genetic medicines company with platform play ambitions, though Editas's modality is editing rather than RNAi.

TypeEmerging player
Description

Korro Bio is a clinical-stage genetic medicines company focused on RNA editing (ADAR-based) targeting hepatic and extra-hepatic tissues. Comparable in modality (RNA-targeting), stage, and emphasis on expanding reach beyond liver through novel delivery chemistries.

TypeDirect peer
Description

Dicerna developed GalNAc-conjugated RNAi therapeutics (acquired by Novo Nordisk in 2021). Closely comparable modality (siRNA targeting liver) and an active RNAi business unit under Novo Nordisk targeting similar rare-disease and cardiometabolic indications as City.

TypeEmerging player
Description

Orbital Therapeutics is an RNA-focused biotech developing novel RNA medicines for immune-related diseases, led by City board member Ron Philip. Comparable in platform ambition to expand the reach of RNA-based therapies and stage/team composition.

TypeEmerging player
Description

Generation Bio develops non-viral genetic medicines (including siRNA/RNAi-like modalities via its ceDNA platform). Tracy Zimmermann (City's CSO) was previously Generation Bio's Chief Development Officer, indicating direct lineage and comparable platform ambition.

TypeDirect peer
Description

ProQR develops RNA-based therapeutics (antisense and siRNA) with a strong focus on inherited ophthalmology and rare diseases (e.g., Stargardt disease programs). Directly comparable to City's CITY-RBP4 indication strategy and RNA-targeting modality.

TypeDirect peer
Description

Alnylam is the founder/incumbent leader in RNAi therapeutics, with five FDA-approved siRNA drugs (ONPATTRO, GIVLAARI, OXLUMO, LEQVIO, AMVUTTRA). Most City founders came from Alnylam and compete directly in the same RNAi modality targeting shared indications (e.g., Factor XI for anticoagulation, hepatic delivery).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

City Therapeutics

RNAi Therapeuticscitytx.com

City Therapeutics is a Cambridge, MA-based clinical-stage biopharmaceutical company developing next-generation RNA interference (RNAi) therapeutics using proprietary cityRNA trigger molecules and extra-hepatic delivery technology to address diseases including thromboembolic disorders, Stargardt disease, and geographic atrophy, serving patients with significant unmet medical need.

What City Therapeutics does

City Therapeutics, Inc. is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company founded in October 2024 by former Alnylam Pharmaceuticals RNAi pioneers, including John Maraganore, Ph.D. (founding CEO of Alnylam, now Executive Chair) and several co-founders with deep Alnylam lineage. The company is developing next-generation RNA interference (RNAi) therapeutics built on a proprietary engineering platform centered on cityRNA (Cleavage-Inducing Tiny RNAs) trigger molecules paired with novel targeting ligands that enable extra-hepatic delivery of siRNAs to tissues beyond the liver, including ocular, CNS, and other tissue types. This extra-hepatic capability is positioned as a key differentiator from current FDA-approved RNAi medicines, which are largely restricted to liver targets.

The company's lead clinical asset is CITY-FXI, a Factor XI-targeting RNAi therapeutic in Phase 1 development in the United Kingdom for thromboembolic diseases, designed to provide anticoagulation with reduced bleeding risk. Its second disclosed program is CITY-RBP4, a preclinical RNAi therapy targeting RBP4 for Stargardt disease and geographic atrophy, with a planned regulatory submission in mid-2026. The pipeline also includes undisclosed hepatic, ocular, and CNS programs, with the company targeting 1-2 INDs per year starting in 2026.

City Therapeutics is pre-revenue and has not yet commercialized any product. Its business model combines future drug commercialization with licensing and partnership economics: it has entered strategic collaborations with Biogen (up to approximately $1 billion in potential milestones plus tiered royalties for CNS) and Bausch + Lomb (up to $485 million in milestones plus royalties for geographic atrophy), each including convertible note investments representing minority equity. To date the company has raised over $230 million across a $135 million Series A (October 2024, led by ARCH Venture Partners) and a $99.5 million Series B (June 2026, led by Viking Global Investors and Sofinnova Investments), with stated runway through 2027.

City Therapeutics firmographics

Firmographics
Name
City Therapeutics
Legal name
CITY THERAPEUTICS, INC.
Website
https://citytx.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
51–100 employees
Short description
City Therapeutics is a Cambridge, MA-based clinical-stage biopharmaceutical company developing next-generation RNA interference (RNAi) therapeutics using proprietary cityRNA trigger molecules and extra-hepatic delivery technology to address diseases including thromboembolic disorders, Stargardt disease, and geographic atrophy, serving patients with significant unmet medical need.
Ownership category
akta.pro rank

City Therapeutics industry classification

Industry
Product category
RNAi Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • RNAi therapeutics
  • SiRNA engineering
  • Biopharmaceutical development
  • Gene silencing medicines
  • Extra-hepatic drug delivery

Where City Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

City Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Commercialization: Pre-revenue clinical-stage biotech developing RNAi therapeutics for rare diseases and specialty conditions. Revenue will come from product sales upon regulatory approval.
  2. Partnership Milestone Payments: Upfront payments and development milestones from strategic partnerships including up to approximately $1 billion from Biogen and up to $485 million from Bausch + Lomb, plus tiered royalties on net sales
  3. Equity Investments from Partners: Strategic investments from pharmaceutical partners including $30 million convertible note from Biogen and convertible note from Bausch + Lomb representing minority equity interest

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

City Therapeutics product offering

Product offering

Core offering

City Therapeutics develops next-generation RNA interference (RNAi)-based therapeutics using its proprietary cityRNA engineering platform. The company is advancing a pipeline of investigational medicines targeting Factor XI for thromboembolic diseases and RBP4 for Stargardt disease and geographic atrophy, leveraging novel siRNA trigger molecules and extra-hepatic delivery technologies.

Product overview

City Therapeutics is developing a pipeline of next-generation RNAi-based medicines using its proprietary cityRNA technology platform. The company's core products include CITY-FXI (Phase 1 clinical trial for thromboembolic diseases targeting Factor XI) and CITY-RBP4 (preclinical/IND-enabling stage for Stargardt disease and geographic atrophy). The platform enables extra-hepatic delivery of RNAi therapeutics to reach tissues beyond the liver, expanding the therapeutic reach of RNA interference medicines across multiple disease areas including coagulation, ophthalmology, and CNS disorders.

Differentiator

Problem solved

Functional benefit

Products and services

  • CITY-FXI A next-generation RNAi therapeutic candidate targeting Factor XI (FXI) for the prevention of thromboembolic diseases, designed to provide safe anticoagulation with reduced bleeding risk compared to standard-of-care therapies and supporting a simple dosing schedule.
  • CITY-RBP4 An investigational RNAi therapy targeting RBP4 for the treatment of Stargardt disease and geographic atrophy, which silences hepatic expression of the vitamin A carrier protein to reduce toxic retinoid accumulation in the retina.
  • cityRNA Technology Platform A next-generation RNAi engineering platform that enables the design of novel trigger molecules (cityRNAs) with improved potency, specificity, and cellular uptake, paired with precision targeting ligands for extra-hepatic delivery beyond the liver.

Quantifiable outcome

  • CITY-RBP4 suppressed RBP4 and reduced circulating retinol by approximately 90% at 3 mg/kg dose in non-human primates with duration consistent with quarterly or biannual dosing
  • +2 more outcomes

Companies that use City Therapeutics

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles3 records

City Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

City Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • BiogencoreStrategic or Co-development Partner · 27 May 2025Strategic collaboration to develop select novel RNAi therapies for CNS diseases. City Therapeutics leveraging next-generation RNAi engineering technologies combined with Biogen's proprietary drug delivery technology. City receives $16M upfront + $30M convertible note investment, eligible for up to ~$1B in milestones plus tiered royalties. Biogen handles IND-enabling studies and global clinical development.
  • Bausch + LombcoreStrategic or Co-development Partner · 10 January 2025Strategic collaboration focused on development of novel RNAi therapy for geographic atrophy (advanced form of age-related macular degeneration). City leverages next-generation RNAi engineering for intravitreal administration. City eligible for up to $485M in milestones plus royalties. Bausch + Lomb responsible for IND-enabling through commercialization.

Scale indicators8 records

Recent moves6 records

Expansion highlights7 records

City Therapeutics competitors and assessment

Company assessment

Direct peers

  • Arrowhead Pharmaceuticals: Arrowhead develops RNAi-based therapeutics using its TRiM platform with strong focus on extra-hepatic delivery (lung, muscle, CNS, oncology) — directly overlapping with City's cityRNA/extra-hepatic strategy. Comparable clinical-stage pipeline dynamics and partnering model (e.g., Sarepta, Takeda, Amgen deals).
  • Sirnaomics: Sirnaomics develops RNAi-based therapeutics using its PNP (Polypeptide Nano-Particle) delivery platform targeting hepatic and extra-hepatic tissues (e.g., oncology, fibrosis, ocular). Comparable modality, stage, and focus on delivery beyond the liver.
  • Dicerna Pharmaceuticals: Dicerna developed GalNAc-conjugated RNAi therapeutics (acquired by Novo Nordisk in 2021). Closely comparable modality (siRNA targeting liver) and an active RNAi business unit under Novo Nordisk targeting similar rare-disease and cardiometabolic indications as City.
  • ProQR Therapeutics: ProQR develops RNA-based therapeutics (antisense and siRNA) with a strong focus on inherited ophthalmology and rare diseases (e.g., Stargardt disease programs). Directly comparable to City's CITY-RBP4 indication strategy and RNA-targeting modality.
  • Alnylam Pharmaceuticals: Alnylam is the founder/incumbent leader in RNAi therapeutics, with five FDA-approved siRNA drugs (ONPATTRO, GIVLAARI, OXLUMO, LEQVIO, AMVUTTRA). Most City founders came from Alnylam and compete directly in the same RNAi modality targeting shared indications (e.g., Factor XI for anticoagulation, hepatic delivery).

Emerging players

  • Wave Life Sciences: Wave develops stereopure oligonucleotide therapeutics (RNAi-like siRNA and other modalities) with a platform analogous to city's cityRNA engineering, focused on CNS, hepatic and extra-hepatic targets. Comparable in clinical stage, modality and pipeline scope.
  • Editas Medicine: Editas develops gene-editing and CRISPR-based therapies, with City CMO Baisong Mei previously serving as EVP/CMO. Comparable as a clinical-stage genetic medicines company with platform play ambitions, though Editas's modality is editing rather than RNAi.
  • Korro Bio: Korro Bio is a clinical-stage genetic medicines company focused on RNA editing (ADAR-based) targeting hepatic and extra-hepatic tissues. Comparable in modality (RNA-targeting), stage, and emphasis on expanding reach beyond liver through novel delivery chemistries.
  • Orbital Therapeutics: Orbital Therapeutics is an RNA-focused biotech developing novel RNA medicines for immune-related diseases, led by City board member Ron Philip. Comparable in platform ambition to expand the reach of RNA-based therapies and stage/team composition.
  • Generation Bio: Generation Bio develops non-viral genetic medicines (including siRNA/RNAi-like modalities via its ceDNA platform). Tracy Zimmermann (City's CSO) was previously Generation Bio's Chief Development Officer, indicating direct lineage and comparable platform ambition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

City Therapeutics social profiles

Digital presence

City Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

City Therapeutics leadership team

Management profile

Number of profiles

Profiles17 records

City Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

City Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about City Therapeutics

What does City Therapeutics do?

City Therapeutics develops next-generation RNA interference (RNAi)-based therapeutics using its proprietary cityRNA engineering platform. The company is advancing a pipeline of investigational medicines targeting Factor XI for thromboembolic diseases and RBP4 for Stargardt disease and geographic atrophy, leveraging novel siRNA trigger molecules and extra-hepatic delivery technologies.

Is City Therapeutics a public or private company?

City Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was City Therapeutics founded?

City Therapeutics was founded in 2024. It employs 51 to 100 people.

Where is City Therapeutics based?

City Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does City Therapeutics make money?

Three revenue lines are on record. Drug Commercialization is the primary driver. The others are partnership Milestone Payments and equity Investments from Partners.

Who are City Therapeutics's main competitors?

Direct peers on record are Arrowhead Pharmaceuticals, Sirnaomics, Dicerna Pharmaceuticals, ProQR Therapeutics and Alnylam Pharmaceuticals. Emerging players are Wave Life Sciences, Editas Medicine, Korro Bio, Orbital Therapeutics and Generation Bio.

Does City Therapeutics have an API?

No public API is recorded for City Therapeutics.

What industry is City Therapeutics in?

City Therapeutics's product category is RNAi Therapeutics. Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing), with a secondary code of HLAAADAE, RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldCity Therapeutics (NASDAQ:CTY) Coverage Initiated by Analysts at The Goldman Sachs GroupGoldman Sachs initiated coverage on City Therapeutics with an early-stage biotech rating, while Jefferies, Stifel, and Oppenheimer issued buy or outperform ratings with price targets. The stock opened at $19.62, and insiders Arch Venture Partners and director Robert Nelsen each bought 170,000 shares at $18.00. The company also dosed the first participant in a Phase 1 trial of CITY-RBP4 for Stargardt disease.Defense WorldCity Therapeutics (NASDAQ:CTY) Now Covered by Analysts at Jefferies Financial GroupJefferies initiated coverage on City Therapeutics with a Buy rating and a $32 price target. The stock opened at $19.62, and the consensus price target is $37.33. Major shareholder Arch Venture Partners and director Robert Nelsen each purchased 170,000 shares at $18 each.Investing.comGoldman Sachs initiates City Therapeutics stock at Early-Stage BiotechGoldman Sachs initiated City Therapeutics with an Early-Stage Biotech rating, citing its RNAi pipeline. The firm estimates $15 billion in global peak sales for CITY-FXI by 2045, with Phase 2 data expected in mid-2027. The stock trades at $18.67, down 16.7% over six months.Investing.comJefferies initiates City Therapeutics stock with buy ratingJefferies initiated City Therapeutics with a buy rating and a $32 price target, citing its RNAi platform and three lead GalNAc siRNA programs. The stock trades at $18.67, down 16.7% over six months, with catalysts expected in 12-18 months. The company holds more cash than debt.Stock TitanCity Therapeutics gets ASH oral slot for Phase 1 dataCity Therapeutics will present Phase 1 data for CITY-FXI, an RNAi therapeutic for thromboembolic diseases, at the ASH Annual Meeting on December 12, 2026. The oral presentation covers single-ascending dose results from healthy volunteers and adults with Factor V Leiden or prothrombin G20210A mutation. A poster will also present preclinical data for CITY-TFR2 targeting anemia of chronic disease.Business & FinancialCity Therapeutics To Present At Upcoming November Investor ConferencesCity Therapeutics will present at Stifel's 2026 Healthcare Conference in New York on November 10 and Jefferies' Global Healthcare Conference in London on November 16, 2026. The company's lead programs include CITY-FXI for thromboembolic diseases, CITY-RBP4 for retinal diseases, and CITY-TFR2 for anemia.Markets DailyCity Therapeutics (NASDAQ:CTY) Stock Moved Up to Hold by Wall Street ZenWall Street Zen upgraded City Therapeutics to a hold rating. Major shareholder Arch Venture Partners Xii and director Robert Nelsen each bought 170,000 shares at $18.00 each on October 19th, increasing their ownership by 1.26%.医药魔方-致力于数据赋能医药创新,助力高效决策与数智化转型siRNA Sector Heats Up With IPOs, Acquisitions and Billion-Dollar LicencesThe RNAi sector is seeing a surge in capital and dealmaking, with City Therapeutics raising about $230 million in an IPO after prior rounds, Merck acquiring Silence Therapeutics for $1.3 billion, and ADARx raising over $500 million. These moves signal renewed investor interest in nucleic-acid medicines.The future of tradingCity Therapeutics Sets Advance Notice Rules for Stockholder ProposalsCity Therapeutics' amended bylaws took effect October 15, 2026, requiring advance notice for stockholder proposals and board nominations. A revised certificate of incorporation filed October 19, 2026, eliminated written consent and special meetings, authorizing 500 million common shares and 10 million preferred shares.Business & FinancialCity Therapeutics Announces Closing Of $230.0 Million Upsized Initial Public Offering, Including Full Exercise Of Underwriters' Option To Purchase Additional SharesCity Therapeutics closed its $230 million upsized IPO, with the stock trading on Nasdaq under ticker CTY. Goldman Sachs, Jefferies, Stifel, and Oppenheimer acted as joint book-running managers. The company's lead programs include CITY-FXI, CITY-RBP4, and CITY-TFR2.